glp 1 and diabetes Indications for GLP-1/GIP RA Summary Sheet Beyond! GLP-1 Agonists - What is

This dual action often leads to steady weight loss and improved metabolic support

The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear

Evidence of such side effects was evident in our latest analysis of brands to watch in 2024, where both Ducolax and Miralax made the list of fastest-growing brands among GLP-1 users in 2023

He then obtained his medical degree from SUNY Health Science Center in Brooklyn